VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
http://www.vrtx.com

SettoreHealthcare
SettoreBiotechnology
Impiegati a tempo pieno3.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Jeffrey Marc LeidenExec. Chairman4,75M19,14M1956
Mr. Michael J. PariniExec. VP & Chief Admin., Legal and Bus. Devel. Officer1,61M3,28M1975
Mr. Amit K. SachdevExec. VP & Chief Patient Officer1,16M9,02M1968
Mr. Stuart A. ArbuckleExec. VP & Chief Commercial Officer1,59M4,45M1966
Dr. Reshma KewalramaniFormer EVP of Global Medicines Devel. & Medical Affairs, Chief Medical Officer and DirectorN/DN/D1973
Gli importi risalgono al giorno 31 dicembre 2018 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for the treatment of cystic fibrosis (CF). The company markets TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF who have specific mutations in their CF transmembrane conductance regulator gene. It is also developing VX-814, which is in Phase II clinical trial and VX-864 that is in Phase I clinical trial for the treatment of alpha-1 antitrypsin deficiency; VX-147 for treating kidney diseases; and CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases. In addition, the company develops VX-150, an inhibitor that is in Phase II clinical trial for acute, neuropathic, and musculoskeletal pain; and VX-561, a potentiator that is in Phase II clinical development; as well as evaluating VX-121, an additional corrector. It sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. The company has collaborations with CRISPR Therapeutics AG; Kymera Therapeutics Inc.; Parion Sciences, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc.; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; X-Chem, Inc.; Molecular Templates, Inc.; and Ribometrix, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Vertex Pharmaceuticals Incorporated al 4 dicembre 2019 è 8. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.
Usando Yahoo accetti che Yahoo e i suoi partners utilizzino cookies per fini di personalizzazione e altre finalità